Renal Cancer Clinical Trials

A listing of Renal Cancer medical research trials actively recruiting patient volunteers. Click on the closest city to find more detailed information on a research study in your area.

 

Arizona

Tucson Arizona 85719

A clinical trial to evaluate treatments using RX-0201 and Everolimus for patients with Metastatic Renal Cell Cancer

California

The Stanford Center for Clinical and Translational Education and Research Recruiting
Palo Alto California 94304

An Open-Label Study of Varlilumab and Nivolumab in Head and Neck, Ovarian, Renal, Colorectal and GBM Cancers

Colorado

University of Colorado Cancer Center
Aurora Colorado 80045

An Open-Label Study of Varlilumab and Nivolumab in Head and Neck, Ovarian, Renal, Colorectal and GBM Cancers

Connecticut

Smilow Cancer Hospital at Yale University Cancer Center Recruiting
New Haven Connecticut 06519

An Open-Label Study of Varlilumab and Nivolumab in Head and Neck, Ovarian, Renal, Colorectal and GBM Cancers

District of Columbia

Georgetown University Recruiting
Washington District of Columbia 20007

An Open-Label Study of Varlilumab and Nivolumab in Head and Neck, Ovarian, Renal, Colorectal and GBM Cancers

Florida

Mount Sinai Medical Center Recruiting and Research Recruiting
Miami Beach Florida 33140

An Open-Label Study of Varlilumab and Nivolumab in Head and Neck, Ovarian, Renal, Colorectal and GBM Cancers

Illinois

Chicago Illinois 60612

A clinical trial to evaluate treatments using RX-0201 and Everolimus for patients with Metastatic Renal Cell Cancer

Indiana

Parkview Research Center
Fort Wayne Indiana 46845

An Open-Label Study of Varlilumab and Nivolumab in Head and Neck, Ovarian, Renal, Colorectal and GBM Cancers

Massachusetts

Dana Farber Cancer Institute Recruiting and Research Recruiting
Boston Massachusetts 02115

An Open-Label Study of Varlilumab and Nivolumab in Head and Neck, Ovarian, Renal, Colorectal and GBM Cancers

Michigan

Barbara Ann Karmanos Cancer Institute Recruiting
Detroit Michigan 48201

An Open-Label Study of Varlilumab and Nivolumab in Head and Neck, Ovarian, Renal, Colorectal and GBM Cancers

New Mexico

Albuquerque New Mexico 87106

A clinical trial to evaluate treatments using RX-0201 and Everolimus for patients with Metastatic Renal Cell Cancer

New York

Memorial Sloan Kettering Cancer Center Recruiting
New York New York 10065

An Open-Label Study of Varlilumab and Nivolumab in Head and Neck, Ovarian, Renal, Colorectal and GBM Cancers

Columbia University Medical Center Recruiting
New York New York 10032

An Open-Label Study of Varlilumab and Nivolumab in Head and Neck, Ovarian, Renal, Colorectal and GBM Cancers

View More ▼

Bronx New York 10467

A clinical trial to evaluate treatments using RX-0201 and Everolimus for patients with Metastatic Renal Cell Cancer

New York New York 10065

A clinical trial to evaluate treatments using RX-0201 and Everolimus for patients with Metastatic Renal Cell Cancer

UPDATED

New York New York 10065

Patients are needed to participate in a clinical research study evaluating LAG525 and PDR001 for the treatment of Advanced Solid Tumors, Malignancies

UPDATED

New York New York 10032

Patients are needed to participate in a clinical research study evaluating LAG525 and PDR001 for the treatment of Advanced Solid Tumors, Malignancies

New York New York 10021

Patients are needed to participate in a clinical research study of 124IcG250 to evaluate Renal Cancer

North Carolina

UPDATED

Durham North Carolina 27704

Patients are needed to participate in a clinical research study evaluating LAG525 and PDR001 for the treatment of Advanced Solid Tumors, Malignancies

Oregon

Providence Health & Services Recruiting
Portland Oregon 97213

An Open-Label Study of Varlilumab and Nivolumab in Head and Neck, Ovarian, Renal, Colorectal and GBM Cancers

Tennessee

Nashville Tennessee 37203

A clinical trial to evaluate treatments using NIS793 and PDR001 for patients

Texas

UPDATED

Houston Texas 77030-4009

Patients are needed to participate in a clinical research study evaluating LAG525 and PDR001 for the treatment of Advanced Solid Tumors, Malignancies

UPDATED

San Antonio Texas 78229

Patients are needed to participate in a clinical research study evaluating LAG525 and PDR001 for the treatment of Advanced Solid Tumors, Malignancies

Utah

Salt Lake City Utah 84112

A clinical trial to evaluate treatments using RX-0201 and Everolimus for patients with Metastatic Renal Cell Cancer

UPDATED

Salt Lake City Utah 84112

Patients are needed to participate in a clinical research study evaluating LAG525 and PDR001 for the treatment of Advanced Solid Tumors, Malignancies

Virginia

Inova Schar Cancer Institute Research
Fairfax Virginia 22031

An Open-Label Study of Varlilumab and Nivolumab in Head and Neck, Ovarian, Renal, Colorectal and GBM Cancers

View More ▼

Charlottesville Virginia 22908

Patients are needed to participate in a clinical research study of Durvalumab, Tremelimumab and Poly ICLC

Washington

Seattle Washington 98101

A clinical trial to evaluate treatments using RX-0201 and Everolimus for patients with Metastatic Renal Cell Cancer

Australia

UPDATED

Heidelberg Victoria 3084

Patients are needed to participate in a clinical research study evaluating LAG525 and PDR001 for the treatment of Advanced Solid Tumors, Malignancies

Malvern Victoria 3144

A clinical trial seeking patients for a research study of Genolimzumab injection

Melbourne Victoria 3004

A clinical trial seeking patients for a research study of Genolimzumab injection

Nedlands Western Australia 6009

A clinical trial seeking patients for a research study of Genolimzumab injection

UPDATED

Westmead New South Wales 2145

Patients are needed to participate in a clinical research study evaluating LAG525 and PDR001 for the treatment of Advanced Solid Tumors, Malignancies

Belgium

UPDATED

Leuven 3000

Patients are needed to participate in a clinical research study evaluating LAG525 and PDR001 for the treatment of Advanced Solid Tumors, Malignancies

Canada

UPDATED

Toronto Ontario M5G 2M9

Patients are needed to participate in a clinical research study evaluating LAG525 and PDR001 for the treatment of Advanced Solid Tumors, Malignancies

Germany

UPDATED

Heidelberg 69120

Patients are needed to participate in a clinical research study evaluating LAG525 and PDR001 for the treatment of Advanced Solid Tumors, Malignancies

UPDATED

Würzburg 97080

Patients are needed to participate in a clinical research study evaluating LAG525 and PDR001 for the treatment of Advanced Solid Tumors, Malignancies

Hong Kong

UPDATED

Hong Kong

Patients are needed to participate in a clinical research study evaluating LAG525 and PDR001 for the treatment of Advanced Solid Tumors, Malignancies

Italy

UPDATED

Milano MI 20133

Patients are needed to participate in a clinical research study evaluating LAG525 and PDR001 for the treatment of Advanced Solid Tumors, Malignancies

UPDATED

Modena MO 41100

Patients are needed to participate in a clinical research study evaluating LAG525 and PDR001 for the treatment of Advanced Solid Tumors, Malignancies

Japan

UPDATED

Fukuoka 811-1395

Patients are needed to participate in a clinical research study evaluating LAG525 and PDR001 for the treatment of Advanced Solid Tumors, Malignancies

Suita Osaka 5650871

Patients are needed to participate in a clinical research study of Mogamulizumab and Nivolumab to evaluate Gastric Cancer, Esophageal Cancer, Lung Cancer or Renal Cancer

Singapore

UPDATED

Singapore 119228

Patients are needed to participate in a clinical research study evaluating LAG525 and PDR001 for the treatment of Advanced Solid Tumors, Malignancies

UPDATED

Singapore 169610

Patients are needed to participate in a clinical research study evaluating LAG525 and PDR001 for the treatment of Advanced Solid Tumors, Malignancies

Spain

UPDATED

Barcelona Catalunya 08035

Patients are needed to participate in a clinical research study evaluating LAG525 and PDR001 for the treatment of Advanced Solid Tumors, Malignancies

UPDATED

Madrid 28007

Patients are needed to participate in a clinical research study evaluating LAG525 and PDR001 for the treatment of Advanced Solid Tumors, Malignancies